In developing a targeted inhalation therapy for lung cancer, Dr. Minko used the multi-tier targeted treatment approach that focused on suppression of all four types of EGFR-TKs by a pool of siRNAs. It also included 1) induction of cell death by an anticancer drug, 2) local inhalation delivery of therapeutic agents to the lungs (passive targeting), 3) active receptor-mediated targeting of the therapy specifically to cancer cells and 4) increasing the stability, solubility and cellular penetration of siRNA and drug by nanoparticles. The application of the proposed approach demonstrated enhanced efficiency of the treatment of lung cancer and reduced adverse side effects.
Tamara Minko, PhD
Distinguished Professor and Chair, Department of Pharmaceutics
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Thursday, October 24 at 3:00pm to 4:00pm